Critically, clinical database analysis establishes FN1 as a prognostic biomarker, with elevated expression correlating with adverse survival outcomes, and reveals significant co-expression between FN1 and CCND1 across NSCLC tumors, supporting their functional synergy within this network. The gene discussed is CCND1; the disease is non-small cell lung carcinoma.